Induction of mitochondrial dysfunction as a strategy for targeting tumour cells in metabolically compromised microenvironments

Nature Communications

Volumn 5, Issue , 2014, Pages

  Zhang, Xiaonan ^a   Fryknäs, Mårten ^b   Hernlund, Emma ^a   Fayad, Walid ^a,f   De Milito, Angelo ^a   Olofsson, Maria Hägg ^a   Gogvadze, Vladimir ^a   Dang, Long ^c   Påhlman, Sven ^d   Schughart, Leoni A Kunz ^e   Rickardson, Linda ^b   D'Arcy, Padraig ^a   Gullbo, Joachim ^b   Nygren, Peter ^b   Larsson, Rolf ^b   Linder, Stig ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^f NATIONAL RESEARCH CENTRE   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GLUCOSE; HYDRAZONE DERIVATIVE; TRIAZOLE DERIVATIVE; VLX600;

ANIMAL; ANOXIA; AUTOPHAGY; CHEMICALLY INDUCED; DRUG EFFECTS; DRUG SCREENING; FEMALE; GLYCOLYSIS; HCT116 CELL LINE; HT 29 CELL LINE; HUMAN; METABOLISM; MITOCHONDRION; MOUSE; MULTICELLULAR SPHEROID; OXIDATIVE PHOSPHORYLATION; TUMOR CELL CULTURE; TUMOR MICROENVIRONMENT;

ANIMALS; ANOXIA; ANTINEOPLASTIC AGENTS; AUTOPHAGY; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GLUCOSE; GLYCOLYSIS; HCT116 CELLS; HT29 CELLS; HUMANS; HYDRAZONES; MICE; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; SPHEROIDS, CELLULAR; TRIAZOLES; TUMOR CELLS, CULTURED; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894542141     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms4295     Document Type: Article

References (63)

1. Harris, A. L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2, 38-47 (2002). (Pubitemid 37328806)
2. Mellor, H. R. & Callaghan, R. Resistance to chemotherapy in cancer: a complex and integrated cellular response. Pharmacology 81, 275-300 (2008). (Pubitemid 351666917)
3. Sahin, A. A. et al. Tumor proliferative fraction in solid malignant neoplasms. A comparative study of Ki-67 immunostaining and flow cytometric determinations. Am. J. Clin. Pathol. 96, 512-519 (1991).
4. St Croix, B. et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat. Med. 2, 1204-1210 (1996). (Pubitemid 26375403)
5. Gardner, L. B. et al. Hypoxia inhibits G1/S transition through regulation of p27 expression. J. Biol. Chem. 276, 7919-7926 (2001).
6. Tannock, I. F. Tumor physiology and drug resistance. Cancer Metastasis Rev. 20, 123-132 (2001). (Pubitemid 34074688)
7. Kim, J. J. & Tannock, I. F. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat. Rev. Cancer 5, 516-525 (2005). (Pubitemid 40942828)
8. Brown, J. M. The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res. 59, 5863-5870 (1999). (Pubitemid 30004940)
9. van Staveren, W. C. et al. Human cancer cell lines: experimental models for cancer cells in situ? For cancer stem cells? Biochim. Biophys. Acta 1795, 92-103 2009.
10. Pampaloni, F., Reynaud, E. G. & Stelzer, E. H. The third dimension bridges the gap between cell culture and live tissue. Nat. Rev. Mol. Cell Biol. 8, 839-845 (2007). (Pubitemid 47462131)
11. Brown, J. M. & Wilson, W. R. Exploiting tumour hypoxia in cancer treatment. Nat. Rev. Cancer 4, 437-447 (2004). (Pubitemid 38745529)
12. Hirschhaeuser, F. et al. Multicellular tumor spheroids: an underestimated tool is catching up again. J. Biotechnol. 148, 3-15 (2010).
13. Friedrich, J., Ebner, R. & Kunz-Schughart, L. A. Experimental anti-tumor therapy in 3-D: spheroids-old hat or new challenge? Int. J. Radiat. Biol. 83, 849-871 (2007). (Pubitemid 350219104)
14. Li, C. K. The glucose distribution in 9L rat brain multicell tumor spheroids and its effect on cell necrosis. Cancer 50, 2066-2073 (1982). (Pubitemid 13203610)
15. Hirayama, A. et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res. 69, 4918-4925 (2009).
16. Acker, H., Carlsson, J., Mueller-Klieser, W. & Sutherland, R. M. Comparative pO2 measurements in cell spheroids cultured with different techniques. Br. J. Cancer 56, 325-327 (1987). (Pubitemid 17158823)
17. Herrmann, R., Fayad, W., Schwarz, S., Berndtsson, M. & Linder, S. Screening for compounds that induce apoptosis of cancer cells grown as multicellular spheroids. J. Biomol. Screen 13, 1-8 (2008).
18. Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545-15550 (2005). (Pubitemid 41528093)
19. Gribbestad, I. S., Sitter, B., Lundgren, S., Krane, J. & Axelson, D. Metabolite composition in breast tumors examined by proton nuclear magnetic resonance spectroscopy. Anticancer Res. 19, 1737-1746 (1999). (Pubitemid 29392730)
20. Chan, E. C. et al. Metabolic profiling of human colorectal cancer using highresolution magic angle spinning nuclear magnetic resonance (HR-MAS NMR) spectroscopy and gas chromatography mass spectrometry (GC/MS). J. Proteome Res. 8, 352-361 (2009).
21. Venkatasubramanian, R., Henson, M. A. & Forbes, N. S. Incorporating energy metabolism into a growth model of multicellular tumor spheroids. J. Theor. Biol. 242, 440-453 (2006). (Pubitemid 44232821)
22. Walenta, S., Doetsch, J., Mueller-Klieser, W. & Kunz-Schughart, L. A. Metabolic imaging in multicellular spheroids of oncogene-transfected fibroblasts. J. Histochem. Cytochem. 48, 509-522 (2000). (Pubitemid 30210355)
23. Jain, R. K. Delivery of novel therapeutic agents in tumors: physiological barriers and strategies. J. Natl Cancer Inst. 81, 570-576 (1989). (Pubitemid 19104487)
24. Kobayashi, H. et al. Acquired multicellular-mediated resistance to alkylating agents in cancer. Proc. Natl Acad. Sci. USA 90, 3294-3298 (1993). (Pubitemid 23111352)
25. Rao, R. V. et al. Coupling endoplasmic reticulum stress to the cell death program: role of the ER chaperone GRP78. FEBS Lett. 514, 122-128 (2002). (Pubitemid 34273925)
26. Osada-Oka, M., Hashiba, Y., Akiba, S., Imaoka, S. & Sato, T. Glucose is necessary for stabilization of hypoxia-inducible factor-1alpha under hypoxia: contribution of the pentose phosphate pathway to this stabilization. FEBS Lett. 584, 3073-3079 (2010).
27. Leek, R. D., Stratford, I. & Harris, A. L. The role of hypoxia-inducible factor-1 in three-dimensional tumor growth, apoptosis, and regulation by the insulin-signaling pathway. Cancer Res. 65, 4147-4152 (2005). (Pubitemid 40775652)
28. Klionsky, D. J. et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 4, 151-175 (2008). (Pubitemid 351231180)
29. Bjorkoy, G. et al. p62/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death. J. Cell Biol. 171, 603-614 (2005). (Pubitemid 41668720)
30. Shintani, T. & Klionsky, D. J. Autophagy in health and disease: a double-edged sword. Science 306, 990-995 (2004). (Pubitemid 39482894)
31. Vande Velde, C. et al. BNIP3 and genetic control of necrosis-like cell death through the mitochondrial permeability transition pore. Mol. Cell Biol. 20, 5454-5468 (2000). (Pubitemid 30482883)
32. Kuhajda, F. P. AMP-activated protein kinase and human cancer: cancer metabolism revisited. Int. J. Obes. (Lond.) 32(Suppl 4): S36-S41 (2008).
33. Wullschleger, S., Loewith, R. & Hall, M. N. TOR signaling in growth and metabolism. Cell 124, 471-484 (2006). (Pubitemid 43199434)
34. Arteel, G. E., Thurman, R. G. & Raleigh, J. A. Reductive metabolism of the hypoxia marker pimonidazole is regulated by oxygen tension independent of the pyridine nucleotide redox state. Eur. J. Biochem. 253, 743-750 (1998). (Pubitemid 28223543)
35. Chun, S. Y. et al. Oncogenic KRAS modulates mitochondrial metabolism in human colon cancer cells by inducing HIF-1alpha and HIF-2alpha target genes. Mol. Cancer 9, 293 (2010).
36. Villani, G. & Attardi, G. In vivo control of respiration by cytochrome c oxidase in human cells. Free Radic. Biol. Med. 29, 202-210 (2000).
37. Luo, J., Solimini, N. L. & Elledge, S. J. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell 136, 823-837 (2009).
38. Denkert, C. et al. Mass spectrometry-based metabolic profiling reveals different metabolite patterns in invasive ovarian carcinomas and ovarian borderline tumors. Cancer Res. 66, 10795-10804 (2006). (Pubitemid 44876975)
39. Wang, P. Y. et al. Increased oxidative metabolism in the Li-Fraumeni syndrome. N. Engl. J. Med. 368, 1027-1032 (2013).
40. Whitaker-Menezes, D. et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 10, 4047-4064 (2011).
41. Wallace, D. C. Mitochondria and cancer. Nat. Rev. Cancer 12, 685-698 (2012).
42. Sanchez-Alvarez, R. et al. Mitochondrial dysfunction in breast cancer cells prevents tumor growth: understanding chemoprevention with metformin. Cell Cycle 12, 172-182 (2013).
43. Salem, A. F., Whitaker-Menezes, D., Howell, A., Sotgia, F. & Lisanti, M. P. Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle 11, 4174-4180 (2012).
44. Bernal, S. D., Lampidis, T. J., McIsaac, R. M. & Chen, L. B. Anticarcinoma activity in vivo of rhodamine 123, a mitochondrial-specific dye. Science 222, 169-172 (1983). (Pubitemid 13008790)
45. Lampidis, T. J., Bernal, S. D., Summerhayes, I. C. & Chen, L. B. Selective toxicity of rhodamine 123 in carcinoma cells in vitro. Cancer Res. 43, 716-720 (1983). (Pubitemid 13193870)
46. Momose, I. et al. Mitochondrial inhibitors show preferential cytotoxicity to human pancreatic cancer PANC-1 cells under glucose-deprived conditions. Biochem. Biophys. Res. Commun. 392, 460-466 (2010).
47. Abou-Khalil, S., Abou-Khalil, W. H., Planas, L., Tapiero, H. & Lampidis, T. J. Interaction of rhodamine 123 with mitochondria isolated from drug-sensitive and-resistant Friend leukemia cells. Biochem. Biophys. Res. Commun. 127, 1039-1044 (1985). (Pubitemid 15040523)
48. Cheng, G. et al. Mitochondria-targeted drugs synergize with 2-deoxyglucose to trigger breast cancer cell death. Cancer Res. 72, 2634-2644 (2012).
49. Owen, M. R., Doran, E. & Halestrap, A. P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348(Pt 3): 607-614 (2000). (Pubitemid 30410251)
50. Brunmair, B. et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions? Diabetes 53, 1052-1059 (2004). (Pubitemid 38436618)
51. Evans, J. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R. & Morris, A. D. Metformin and reduced risk of cancer in diabetic patients. BMJ 330, 1304-1305 (2005). (Pubitemid 40813563)
52. Hirsch, H. A., Iliopoulos, D., Tsichlis, P. N. & Struhl, K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 69, 7507-7511 (2009).
53. Rocha, G. Z. et al. Metformin amplifies chemotherapy-induced AMPK activation and antitumoral growth. Clin. Cancer Res. 17, 3993-4005 (2011).
54. Fayad, W. et al. Identification of agents that induce apoptosis of multicellular tumour spheroids: enrichment for mitotic inhibitors with hydrophobic properties. Chem. Biol. Drug Des. 78, 547-557 (2011).
55. Lu, J., Kunimoto, S., Yamazaki, Y., Kaminishi, M. & Esumi, H. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci. 95, 547-552 (2004). (Pubitemid 38832706)
56. Ravizza, R. et al. Effect of HIF-1 modulation on the response of two-and three-dimensional cultures of human colon cancer cells to 5-fluorouracil. Eur. J. Cancer 45, 890-898 (2009).
57. Bunz, F. et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. Science 282, 1497-1501 (1998). (Pubitemid 28538613)
58. Lindhagen, E., Nygren, P. & Larsson, R. The fluorometric microculture cytotoxicity assay. Nat. Protoc. 3, 1364-1369 (2008).
59. Friedrich, J. et al. A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J. Biomol. Screen. 12, 925-937 (2007). (Pubitemid 47548596)
60. Hägg, M. et al. A novel high-through-put assay for screening of pro-apoptotic drugs. Invest. New Drugs 20, 253-259 (2002). (Pubitemid 34823753)
61. Holmquist-Mengelbier, L. et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10, 413-423 (2006). (Pubitemid 44693470)
62. Schmidt-Mende, J., Gogvadze, V., Hellstrom-Lindberg, E. & Zhivotovsky, B. Early mitochondrial alterations in ATRA-induced cell death. Cell Death Differ. 13, 119-128 (2006).
63. Chance, B. & Williams, G. R. Respiratory enzymes in oxidative phosphorylation. I. Kinetics of oxygen utilization. J. Biol. Chem. 217, 383-393 (1955).